A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes the use of miniature lungs and colons to help test Covid-19 treatments.
According to several studies, the risk of contracting COVID-19 or developing a serious case of the disease may be greater depending on blood type.
In a BioSpace interview, Sorrento Therapeutics executives emphasized the stringent process the company went through in identifying the antibody STI-1499, which demonstrated 100 percent inhibition of SARS-CoV-2 in laboratory tests.
As the world battles the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2, biopharma and biotech companies are approaching the fight with various weapons – repurposed drugs, antivirals, vaccines and clinical antibodies. One of the companies deeply involved in clinical antibody development against COVID-19 is San Diego-based Sorrento Therapeutics.
San Diego-based Sorrento Therapeutics is teaming up with New York City-based Mount Sinai Health System to develop an antibody cocktail called COVI-SHIELD to treat COVID-19.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.